Bausch Health Companies Inc. (BHC)

NYSE: BHC · Real-Time Price · USD
7.47
+0.08 (1.08%)
Dec 20, 2024, 4:00 PM EST - Market closed
1.08%
Market Cap 2.75B
Revenue (ttm) 9.47B
Net Income (ttm) -178.00M
Shares Out 367.80M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE 1.76
Dividend n/a
Ex-Dividend Date n/a
Volume 1,132,628
Open 7.33
Previous Close 7.39
Day's Range 7.33 - 7.60
52-Week Range 3.96 - 11.46
Beta 0.69
Analysts Hold
Price Target 7.25 (-2.95%)
Earnings Date Oct 30, 2024

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,270
Stock Exchange NYSE
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2023, Bausch Health Companies's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $7.25, which is a decrease of -2.95% from the latest price.

Price Target
$7.25
(-2.95% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Contact lens maker Bausch + Lomb says it is exploring sale

Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.

9 days ago - Reuters

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a...

9 days ago - Accesswire

Bausch + Lomb Responds to Rumors of a Potential Sale

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement...

9 days ago - Business Wire

Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday.

Other symbols: MPLAY
10 days ago - Benzinga

Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affili...

10 days ago - Business Wire

Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News

Bausch Health Companies Inc.'s debt burden remains a critical issue, with over $21 billion in long-term debt, making a sale of Bausch + Lomb Corporation a potential solution. Bausch + Lomb's Q3 perfor...

15 days ago - Seeking Alpha

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation...

16 days ago - Accesswire

Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors

Bausch Health Companies is undervalued, with a positive outlook for 2024 and solvency reassurance for 2025. The complete spin-off of Bausch + Lomb (B+L) will benefit BHC and is expected to improve its...

18 days ago - Seeking Alpha

Bausch Health Appoints New Chief Medical Officer and Head of R&D

LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medi...

19 days ago - Accesswire

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug

The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.

4 weeks ago - Reuters

Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)...

4 weeks ago - Accesswire

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and ben...

4 weeks ago - Accesswire

Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...

5 weeks ago - Business Wire

Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Transcript

Bausch Health Companies, Inc. (NYSE:BHC) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conf...

7 weeks ago - Seeking Alpha

Bausch Health Announces Third Quarter 2024 Results

Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1 Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic...

Other symbols: NHC
7 weeks ago - Accesswire

Bausch + Lomb Announces Third-Quarter 2024 Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quar...

7 weeks ago - Business Wire

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterolog...

7 weeks ago - Accesswire

Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces

Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb BLCO, the Financial Times reported.

Other symbols: TPGBX
2 months ago - Benzinga

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. ...

2 months ago - Business Wire

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch ...

2 months ago - Accesswire

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter...

2 months ago - Business Wire

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1 LAVAL, QC / ACCESSWIRE / Oc...

2 months ago - Accesswire

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...

2 months ago - Business Wire

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could fetch a premium price. Bausch + Lomb's stable business and the recent acquisit...

3 months ago - Seeking Alpha

With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels

Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward ear...

3 months ago - Seeking Alpha